TY - JOUR
T1 - Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
AU - Yang, James C.
AU - Sherry, Richard M.
AU - Steinberg, Seth M.
AU - Topalian, Suzanne L.
AU - Schwartzentruber, Douglas J.
AU - Hwu, Patrick
AU - Seipp, Claudia A.
AU - Rogers-Freezer, Linda
AU - Morton, Kathleen E.
AU - White, Donald E.
AU - Liewehr, David J.
AU - Merino, Maria J.
AU - Rosenberg, Steven A.
PY - 2003/8/15
Y1 - 2003/8/15
N2 - Purpose: This three-arm randomized study compares response rates and overall survival of patients with metastatic renal cell cancer (RCC) receiving high-dose or one of two low-dose interleukin-2 (IL-2) regimens. Patients and Methods: Patients with measurable metastatic RCC and a good performance status were randomized to receive either 720,000 U/kg (high-dose [HD]) or 72,000 U/kg (low-dose [LD]), both given by intravenous (IV) bolus every 8 hours. After randomly assigning 117 patients, a third arm of low-dose daily subcutaneous IL-2 was added, and an additional 283 patients were randomly assigned. Results: A total of 156 patients were randomly assigned to HD IV IL-2, and 150 patients to LD IV IL-2. Toxicities were less frequent with LD IV IL-2 (especially hypotension), but there were no IL-2-related deaths in any arm. There was a higher response proportion with HD IV IL-2 (21%) versus LD IV IL-2 (13%; P = .048) but no overall survival difference. The response rate of subcutaneous IL-2 (10%, partial response and complete response) was similar to that of LD IV IL-2, differing from HD IV (P = .033). Response durability and survival in completely responding patients was superior with HD IV compared with LD IV therapy (P = .04). Conclusion: Major tumor regressions, as well as complete responses, were seen with all regimens tested. IL-2 was more clinically active at maximal doses, although this did not produce an overall survival benefit. The immunological factors which constrain the curative potential of IL-2 to only a small percentage of patients need to be further elucidated.
AB - Purpose: This three-arm randomized study compares response rates and overall survival of patients with metastatic renal cell cancer (RCC) receiving high-dose or one of two low-dose interleukin-2 (IL-2) regimens. Patients and Methods: Patients with measurable metastatic RCC and a good performance status were randomized to receive either 720,000 U/kg (high-dose [HD]) or 72,000 U/kg (low-dose [LD]), both given by intravenous (IV) bolus every 8 hours. After randomly assigning 117 patients, a third arm of low-dose daily subcutaneous IL-2 was added, and an additional 283 patients were randomly assigned. Results: A total of 156 patients were randomly assigned to HD IV IL-2, and 150 patients to LD IV IL-2. Toxicities were less frequent with LD IV IL-2 (especially hypotension), but there were no IL-2-related deaths in any arm. There was a higher response proportion with HD IV IL-2 (21%) versus LD IV IL-2 (13%; P = .048) but no overall survival difference. The response rate of subcutaneous IL-2 (10%, partial response and complete response) was similar to that of LD IV IL-2, differing from HD IV (P = .033). Response durability and survival in completely responding patients was superior with HD IV compared with LD IV therapy (P = .04). Conclusion: Major tumor regressions, as well as complete responses, were seen with all regimens tested. IL-2 was more clinically active at maximal doses, although this did not produce an overall survival benefit. The immunological factors which constrain the curative potential of IL-2 to only a small percentage of patients need to be further elucidated.
UR - http://www.scopus.com/inward/record.url?scp=0042914703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042914703&partnerID=8YFLogxK
U2 - 10.1200/JCO.2003.02.122
DO - 10.1200/JCO.2003.02.122
M3 - Article
C2 - 12915604
AN - SCOPUS:0042914703
SN - 0732-183X
VL - 21
SP - 3127
EP - 3132
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 16
ER -